vs

Side-by-side financial comparison of Limbach Holdings, Inc. (LMB) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

REPLIGEN CORP is the larger business by last-quarter revenue ($197.9M vs $186.9M, roughly 1.1× Limbach Holdings, Inc.). REPLIGEN CORP runs the higher net margin — 6.7% vs 6.6%, a 0.1% gap on every dollar of revenue. On growth, Limbach Holdings, Inc. posted the faster year-over-year revenue change (30.1% vs 13.6%). Limbach Holdings, Inc. produced more free cash flow last quarter ($27.9M vs $17.6M). Over the past eight quarters, Limbach Holdings, Inc.'s revenue compounded faster (25.3% CAGR vs 14.4%).

Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

LMB vs RGEN — Head-to-Head

Bigger by revenue
RGEN
RGEN
1.1× larger
RGEN
$197.9M
$186.9M
LMB
Growing faster (revenue YoY)
LMB
LMB
+16.4% gap
LMB
30.1%
13.6%
RGEN
Higher net margin
RGEN
RGEN
0.1% more per $
RGEN
6.7%
6.6%
LMB
More free cash flow
LMB
LMB
$10.3M more FCF
LMB
$27.9M
$17.6M
RGEN
Faster 2-yr revenue CAGR
LMB
LMB
Annualised
LMB
25.3%
14.4%
RGEN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LMB
LMB
RGEN
RGEN
Revenue
$186.9M
$197.9M
Net Profit
$12.3M
$13.3M
Gross Margin
25.7%
52.5%
Operating Margin
9.4%
9.0%
Net Margin
6.6%
6.7%
Revenue YoY
30.1%
13.6%
Net Profit YoY
25.0%
143.9%
EPS (diluted)
$1.01
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LMB
LMB
RGEN
RGEN
Q4 25
$186.9M
$197.9M
Q3 25
$184.6M
$188.8M
Q2 25
$142.2M
$182.4M
Q1 25
$133.1M
$169.2M
Q4 24
$143.7M
$174.1M
Q3 24
$133.9M
$154.9M
Q2 24
$122.2M
$154.1M
Q1 24
$119.0M
$151.3M
Net Profit
LMB
LMB
RGEN
RGEN
Q4 25
$12.3M
$13.3M
Q3 25
$8.8M
$14.9M
Q2 25
$7.8M
$14.9M
Q1 25
$10.2M
$5.8M
Q4 24
$9.8M
$-30.3M
Q3 24
$7.5M
$-654.0K
Q2 24
$6.0M
$3.3M
Q1 24
$7.6M
$2.1M
Gross Margin
LMB
LMB
RGEN
RGEN
Q4 25
25.7%
52.5%
Q3 25
24.2%
53.2%
Q2 25
28.0%
50.0%
Q1 25
27.6%
53.6%
Q4 24
30.3%
26.1%
Q3 24
27.0%
50.0%
Q2 24
27.4%
49.8%
Q1 24
26.1%
49.5%
Operating Margin
LMB
LMB
RGEN
RGEN
Q4 25
9.4%
9.0%
Q3 25
7.2%
8.9%
Q2 25
7.5%
7.6%
Q1 25
5.9%
3.9%
Q4 24
9.1%
-17.7%
Q3 24
8.1%
-5.1%
Q2 24
6.7%
1.0%
Q1 24
5.5%
1.3%
Net Margin
LMB
LMB
RGEN
RGEN
Q4 25
6.6%
6.7%
Q3 25
4.8%
7.9%
Q2 25
5.5%
8.2%
Q1 25
7.7%
3.4%
Q4 24
6.9%
-17.4%
Q3 24
5.6%
-0.4%
Q2 24
4.9%
2.2%
Q1 24
6.4%
1.4%
EPS (diluted)
LMB
LMB
RGEN
RGEN
Q4 25
$1.01
$0.24
Q3 25
$0.73
$0.26
Q2 25
$0.64
$0.26
Q1 25
$0.85
$0.10
Q4 24
$0.81
$-0.55
Q3 24
$0.62
$-0.01
Q2 24
$0.50
$0.06
Q1 24
$0.64
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LMB
LMB
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$11.3M
$767.6M
Total DebtLower is stronger
$30.5M
$542.2M
Stockholders' EquityBook value
$195.7M
$2.1B
Total Assets
$381.1M
$2.9B
Debt / EquityLower = less leverage
0.16×
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LMB
LMB
RGEN
RGEN
Q4 25
$11.3M
$767.6M
Q3 25
$9.8M
$748.7M
Q2 25
$38.9M
$708.9M
Q1 25
$38.1M
$697.2M
Q4 24
$44.9M
$757.4M
Q3 24
$51.2M
$784.0M
Q2 24
$59.5M
$809.1M
Q1 24
$48.2M
$780.6M
Total Debt
LMB
LMB
RGEN
RGEN
Q4 25
$30.5M
$542.2M
Q3 25
$56.3M
$537.9M
Q2 25
$28.4M
Q1 25
$23.7M
Q4 24
$23.6M
$525.6M
Q3 24
$20.5M
Q2 24
$19.7M
Q1 24
$19.4M
Stockholders' Equity
LMB
LMB
RGEN
RGEN
Q4 25
$195.7M
$2.1B
Q3 25
$181.6M
$2.1B
Q2 25
$170.5M
$2.1B
Q1 25
$161.1M
$2.0B
Q4 24
$153.5M
$2.0B
Q3 24
$142.2M
$2.0B
Q2 24
$133.0M
$2.0B
Q1 24
$125.5M
$2.0B
Total Assets
LMB
LMB
RGEN
RGEN
Q4 25
$381.1M
$2.9B
Q3 25
$409.1M
$2.9B
Q2 25
$343.0M
$2.9B
Q1 25
$336.4M
$2.9B
Q4 24
$352.1M
$2.8B
Q3 24
$324.4M
$2.8B
Q2 24
$303.9M
$2.9B
Q1 24
$289.2M
$2.8B
Debt / Equity
LMB
LMB
RGEN
RGEN
Q4 25
0.16×
0.26×
Q3 25
0.31×
0.26×
Q2 25
0.17×
Q1 25
0.15×
Q4 24
0.15×
0.27×
Q3 24
0.14×
Q2 24
0.15×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LMB
LMB
RGEN
RGEN
Operating Cash FlowLast quarter
$28.1M
$25.7M
Free Cash FlowOCF − Capex
$27.9M
$17.6M
FCF MarginFCF / Revenue
14.9%
8.9%
Capex IntensityCapex / Revenue
0.1%
4.1%
Cash ConversionOCF / Net Profit
2.29×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$41.9M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LMB
LMB
RGEN
RGEN
Q4 25
$28.1M
$25.7M
Q3 25
$13.3M
$48.1M
Q2 25
$2.0M
$28.6M
Q1 25
$2.2M
$15.0M
Q4 24
$19.3M
$39.2M
Q3 24
$4.9M
$49.3M
Q2 24
$16.5M
$42.2M
Q1 24
$-3.9M
$44.7M
Free Cash Flow
LMB
LMB
RGEN
RGEN
Q4 25
$27.9M
$17.6M
Q3 25
$12.8M
$43.4M
Q2 25
$1.2M
$21.5M
Q1 25
$11.0K
$11.4M
Q4 24
$18.0M
$33.6M
Q3 24
$4.6M
$42.3M
Q2 24
$13.2M
$37.4M
Q1 24
$-6.5M
$36.4M
FCF Margin
LMB
LMB
RGEN
RGEN
Q4 25
14.9%
8.9%
Q3 25
7.0%
23.0%
Q2 25
0.8%
11.8%
Q1 25
0.0%
6.8%
Q4 24
12.5%
19.3%
Q3 24
3.4%
27.3%
Q2 24
10.8%
24.3%
Q1 24
-5.5%
24.0%
Capex Intensity
LMB
LMB
RGEN
RGEN
Q4 25
0.1%
4.1%
Q3 25
0.3%
2.5%
Q2 25
0.6%
3.9%
Q1 25
1.7%
2.1%
Q4 24
0.9%
3.2%
Q3 24
0.3%
4.5%
Q2 24
2.7%
3.1%
Q1 24
2.1%
5.5%
Cash Conversion
LMB
LMB
RGEN
RGEN
Q4 25
2.29×
1.93×
Q3 25
1.52×
3.23×
Q2 25
0.26×
1.92×
Q1 25
0.22×
2.57×
Q4 24
1.96×
Q3 24
0.66×
Q2 24
2.77×
12.70×
Q1 24
-0.52×
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LMB
LMB

Owner Direct Relationships Segment$145.0M78%
General Contractor Construction Manager Relationships Segment$41.9M22%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons